• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Merck - Articles and news items

Biocartis and Merck partnership launch second liquid biopsy assay

Industry news / 15 March 2017 / Niamh Marriott, Junior Editor

This collaboration is aimed at jointly developing and commercialising new liquid biopsy RAS biomarker tests for metastatic colorectal cancer (mCRC)…

The Top 21…wealthiest pharma companies

Blog, Z Homepage promo / 6 February 2017 / Niamh Marriott, Digital Editor

Find out who made it to the top of our list of richest pharma companies…

Biocartis launches second liquid biopsy assay

Industry news / 14 December 2016 / Niamh Louise Marriott, Digital Editor

Biocartis launched its second liquid biopsy assay, the Idylla ctKRAS Mutation Assay, which was developed in partnership with Merck…

GSK tops list ranking big pharma’s global access to medicine

Industry news / 14 November 2016 / Niamh Louise Marriott, Digital Content Producer

Read how the 2016 Access to Medicine Index ranks the top 20 pharmaceutical companies on their efforts to improve access to medicine in low- and middle-income countries…

NICE says head and neck cancer drug cetuximab is not cost-effective

Industry news / 7 November 2016 / Niamh Louise Marriott, Digital Content Producer

NICE was reconsidering cetuximab as part of its programme to appraise drugs that are currently available on the Cancer Drugs Fund…

Apitope regains global rights to its multiple sclerosis treatment from Merck

Industry news / 18 October 2016 / Niamh Louise Marriott, Digital Content Producer

In 2009, Apitope granted exclusive worldwide rights to Merck to develop and commercialise ATX-MS-1467 but now have successfully regained…

MSD’s Hepatitis C drug given green light for EU market

Industry news / 9 August 2016 / MSD

Following successful phase 3 clinical trials, in which MSD’s new Hepatitis C drug, Zepatier, performed well, achieving high virologic cure rates across the study, the European Commission has licensed the drug for sale in the European market, specifically for the treatment of chronic hepatitis C virus (HCV) in adults with genotype 1 and 4 infection…

FDA approves Merck’s head and neck cancer drug

Industry news / 8 August 2016 / Merck

Under the FDA’s accelerated approval regulations, Keytruda, a humanized monoclonal antibody that works by increasing the ability of the body’s immune system to help detect and fight tumour cells, is approved based on tumour response rate and durability of response. However, continued approval for the drug may be contingent upon verification and description of clinical benefit in the confirmatory trials…

CHMP positive opinion for Keytruda in NSCLC

Industry news / 27 June 2016 / Victoria White, Digital Content Producer

The CHMP has recommended approval of Keytruda for the treatment of locally advanced or metastatic NSCLC in adults whose tumours express PD-L1…

First patient treated in the Phase III ECHO-301 study

Industry news / 23 June 2016 / Victoria White, Digital Content Producer

ECHO-301 will evaluate Incyte’s epacadostat with Merck’s pembrolizumab as first-line treatment for patients with advanced or metastatic melanoma…

Phase II study of relebactam in UTIs meets primary endpoint

Industry news / 21 June 2016 / Victoria White, Digital Content Producer

The addition of relebactam is designed to restore activity of imipenem against certain imipenem-resistant strains of Gram-negative bacteria…

Keytruda superior to chemotherapy in NSCLC study

Industry news / 17 June 2016 / Victoria White, Digital Content Producer

The KEYNOTE-024 trial investigating Keytruda in patients with previously untreated advanced non-small cell lung cancer has met its primary endpoint…